LY3938577

Phase 2Small molecule

Eli Lilly

LY3938577 is one of 106 small molecule programs targeting Type 2 Diabetes Mellitus. It is currently in Phase 2.

Indications

Total Trials

Active Trials

105

Competitors

Pipeline

Status by Indication[3][1]

Indication

Type 2 Diabetes MellitusActive, not recruiting

Type 2 DiabetesActive, not recruiting

Diabetes Mellitus, Type 2Recruiting

Type 1 Diabetes MellitusActive, not recruiting

Type 2 Diabetes MellitusPhase 1

Active, not recruiting

Type 2 DiabetesPhase 2

Active, not recruiting

Diabetes Mellitus, Type 2Phase 2

Recruiting

Type 1 Diabetes MellitusPhase 1

Active, not recruiting

Competition

Competitive Landscape

885 competitors in Type 2 Diabetes

#DrugCompanyPhaseTrials

Jardiance

Boehringer Ingelheim

Preclinical

31 2

LY3938577

Eli Lilly

Phase 2

3 3

Cysteine Hydrochloride

Novartis

Preclinical

1 4

Inspra

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

2 5

Nexium

DDexcel Pharma Technologies Ltd.

Preclinical

1 6

Inderal

WWyeth-Lederle Vaccines

Preclinical

1 7

Forxiga

AstraZeneca

Preclinical

3 8

Acipimox

Boehringer Ingelheim

Preclinical

2 9

GLP-1

RRigshospitalet, Denmark

Preclinical

1 10

Blank Control

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 1Recruiting

Type 1 Diabetes Mellitus

NCT06280703

Q4 2026

Phase 2Active, not recruiting

Diabetes Mellitus, Type 2

NCT07215312

Clinical

Trials by Indication[1]

Type 2 Diabetes Mellitus1 trial

A Study to Investigate the Safety and Tolerability of LY3938577 in Healthy Participants and Participants With Type 2 Diabetes Mellitus

Completed· Eli Lilly logo

Eli Lilly·Phase 1·NCT06132126·66 enrolled

Type 1 Diabetes Mellitus1 trial

A Study of LY3938577 in Healthy Participants and Participants With Type 1 Diabetes Mellitus (T1DM)

Recruiting· Eli Lilly logo

Eli Lilly·Phase 1·NCT06280703·118 enrolled

Diabetes Mellitus, Type 21 trial

A Phase 2, Randomized, Open-Label, Comparator-Controlled Trial to Evaluate the Efficacy and Safety of LY3938577 in Study Participants, With Type 2 Diabetes Previously Treated With Basal Insulin

Active, not recruiting· Eli Lilly logo

Eli Lilly·Phase 2·NCT07215312·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for LY3938577. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — LY3938577 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for LY3938577. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Eli Lilly company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Eli Lilly

LY3938577

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q4 2026

Trials by Indication[1]

Type 2 Diabetes Mellitus1 trial

Type 1 Diabetes Mellitus1 trial

Diabetes Mellitus, Type 21 trial

References

Drug Info

Quick Facts

Related News